Incorporation of CD40 ligand into SHIV virus-like particles (VLP) enhances SHIV-VLP-induced dendritic cell activation and boosts immune responses against HIV.
Engagement of CD40 with CD40L induces dendritic cell (DC) maturation and activation, thereby promoting immune responses. The objective of this study was to investigate whether immunization with chimeric CD40L/SHIV virus-like particles (CD40L/SHIV-VLP) could enhance immune responses to SIV Gag and HIV Env proteins by directly activating DCs. We found that CD83, CD40, and CD86 were significantly up-regulated and significantly increased cytokines production were observed after hCD40L/SHIV-VLP treatment in human CD14(+) monocyte-derived DCs as compared to SHIV-VLP treatment. Mice immunized with mCD40L/SHIV-VLP showed more than a two-fold increase in HIV Env-specific IgG antibody production, an increase in SIV Gag and HIV Env-specific IFN-gamma and IL-4 producing cells, and an increase in HIV Env-specific cytotoxic activity compared to that in SHIV-VLP immunized mice. Furthermore, multifunctional CD4(+) Th1 cells, which simultaneously produce IFN-gamma, IL-2 and TNF-alpha triple cytokines, and CD8(+) T-cells, which produce IFN-gamma were elevated in the mCD40L/SHIV-VLP immunized group. These data demonstrate that chimeric CD40L/SHIV-VLP potently induce DC activation and enhance the magnitude of both humoral and cellular immune responses to the SIV Gag and HIV Env proteins in the mouse model. Therefore, incorporation of CD40L into VLP may represent a novel strategy to develop effective HIV vaccines.
Zhang
Rongxin
R
Molecular Surgeon Research Center, Michael E. DeBakey Department of Surgery, Baylor College of Medicine, Houston, TX 77030, United States.
Zhang
Sheng
S
Li
Min
M
Chen
Changyi
C
Yao
Qizhi
Q
D016915:AIDS Vaccines / Q000276:immunology*; D000818:Animals; D023201:CD40 Ligand / Q000276:immunology*; D002478:Cells, Cultured; D003713:Dendritic Cells / Q000276:immunology*; D006678:HIV / Q000276:immunology; D015483:HIV Antibodies / Q000097:blood; D015658:HIV Infections / Q000276:immunology / Q000517:prevention & control*; D006801:Humans; D007074:Immunoglobulin G / Q000097:blood; D007371:Interferon-gamma / Q000276:immunology; D015847:Interleukin-4 / Q000276:immunology; D051379:Mice; D008810:Mice, Inbred C57BL; D015302:Simian Immunodeficiency Virus / Q000276:immunology; D013601:T-Lymphocytes / Q000276:immunology; D014409:Tumor Necrosis Factor-alpha / Q000276:immunology
D016915:AIDS Vaccines; D015483:HIV Antibodies; D007074:Immunoglobulin G; D014409:Tumor Necrosis Factor-alpha; D023201:CD40 Ligand; D015847:Interleukin-4; D007371:Interferon-gamma
Immunity. 2000 Oct;13(4):453-62
11070164
J Immunol. 2000 Sep 15;165(6):3043-50
10975814
EMBO J. 1999 Apr 1;18(7):1845-57
10202148
J Immunol Methods. 2000 Jun 23;240(1-2):69-78
10854602
Annu Rev Immunol. 1991;9:271-96
1910679
AIDS Res Hum Retroviruses. 2000 Feb 10;16(3):227-36
10710211
J Exp Med. 1990 Nov 1;172(5):1483-93
2230654
Immunol Rev. 1996 Oct;153:85-106
9010720
Trends Immunol. 2001 Oct;22(10):556-60
11574279
J Immunol. 2004 Aug 1;173(3):1951-8
15265929
Blood. 2004 Nov 1;104(9):2810-7
15231570
Ann Hematol. 2005 Jul;84(7):423-8
15812666
Clin Immunol. 2000 Feb;94(2):88-98
10637093
Cancer Gene Ther. 2004 Dec;11(12):808-18
15359290
Blood. 1995 Nov 1;86(9):3295-301
7579430
J Immunol. 1995 Nov 15;155(10):4917-25
7594496
Nat Immunol. 2007 Oct;8(10):1086-94
17873879
J Immunother. 2003 Sep-Oct;26(5):451-60
12973034
J Leukoc Biol. 2000 Jan;67(1):2-17
10647992
Int Immunol. 1998 Nov;10(11):1593-8
9846688
J Virol. 2007 Feb;81(3):1083-94
17108046
J Immunol. 2000 Nov 1;165(9):4910-6
11046016
J Exp Med. 2003 Apr 21;197(8):1059-63
12707303
Annu Rev Immunol. 1994;12:881-922
7516669
Nature. 1998 Jun 4;393(6684):474-8
9624003
J Immunol. 1998 Feb 15;160(4):1666-76
9469423
Cell Adhes Commun. 1998;6(2-3):117-23
9823462
J Immunol. 1999 Jul 1;163(1):174-83
10384114
Proc Natl Acad Sci U S A. 1996 Mar 19;93(6):2588-92
8637918
J Immunol. 2001 May 15;166(10):5917-24
11342606
Blood. 2000 Jul 1;96(1):91-9
10891436
Immunity. 1996 May;4(5):415-9
8630727
J Exp Med. 2000 Mar 20;191(6):927-36
10727455
Expert Opin Biol Ther. 2001 Jul;1(4):571-81
11727495
J Immunol. 2001 May 1;166(9):5346-55
11313370
Virology. 2003 Sep 1;313(2):502-13
12954217
J Immunol. 2000 Jun 15;164(12):6633-9
10843723
J Exp Med. 1995 Jun 1;181(6):2237-47
7760009
J Immunol. 1997 Oct 15;159(8):3838-48
9378971
J Immunol. 2001 May 1;166(9):5448-55
11313382
Blood. 2000 Nov 15;96(10):3499-504
11071647
J Exp Med. 1996 Aug 1;184(2):747-52
8760829
Science. 2006 Mar 31;311(5769):1924-7
16484453
J Immunol. 1997 May 1;158(9):4229-36
9126984
Scand J Immunol. 2001 Jun;53(6):579-87
11422906
J Immunol. 1998 Sep 15;161(6):2804-9
9743339
J Immunol. 2003 Jan 15;170(2):727-34
12517934
Cancer Gene Ther. 2004 Feb;11(2):135-47
14647233
J Immunol. 2002 Mar 15;168(6):2880-6
11884458
J Immunol. 1999 Jan 1;162(1):168-75
9886383
J Immunol. 1995 Nov 1;155(9):4241-7
7594581
Cell Immunol. 1999 Apr 10;193(1):48-58
10202112
Trends Immunol. 2006 Jun;27(6):282-90
16698319
EMBO J. 2000 Jul 3;19(13):3304-13
10880443
J Immunol. 2001 Jul 15;167(2):957-65
11441104
Cancer Gene Ther. 2002 Feb;9(2):202-8
11857039
Annu Rev Immunol. 2000;18:767-811
10837075
Scand J Immunol. 2000 Apr;51(4):377-83
10736110
J Immunol. 1999 Dec 1;163(11):5786-95
10570261
Clin Immunol. 2003 Mar;106(3):231-7
12706410
Science. 2006 Mar 31;311(5769):1875-6
16574856
Res Immunol. 1994 Mar-Apr;145(3):235-9; discussion 244-9
7527581
J Immunol. 1998 Dec 15;161(12):6614-21
9862689
Vaccine. 2004 Nov 25;23(2):139-47
15531030
Blood. 2006 Mar 1;107(5):1989-95
16269614